接受组织型纤溶酶原激活剂治疗的急性心肌梗死患者的死亡或非致命性中风。心肌梗死全国注册研究2的参与者。
Death or nonfatal stroke in patients with acute myocardial infarction treated with tissue plasminogen activator. Participants in the National Registry of Myocardial Infarction 2.
作者信息
Angeja B G, Rundle A C, Gurwitz J H, Gore J M, Barron H V
机构信息
Genentech Inc, South San Francisco, California, USA.
出版信息
Am J Cardiol. 2001 Mar 1;87(5):627-30, A9. doi: 10.1016/s0002-9149(00)01441-7.
Abstract
In a retrospective cohort of patients treated in community hospitals, tissue plasminogen activator (t-PA) was associated with decreased odds of in-hospital death or nonfatal stroke. However, the relative benefit was less evident in older patients and women, and some older subgroups did not benefit from treatment.
摘要
在一个对社区医院接受治疗的患者的回顾性队列研究中，组织型纤溶酶原激活剂（t-PA）与住院死亡或非致死性卒中几率降低相关。然而，这种相对获益在老年患者和女性中不太明显，并且一些老年亚组并未从治疗中获益。
Zotero 插件